top of page

Welcome to
EndoCyclic Therapeutics

Developing First-in-Class Targeted Non-Hormonal

Therapeutic and Diagnostic Agents in Oncology and Women’s Health Using Novel Precision pH-Sensitive Peptides

Mission

Oncology

Developing tolerable, “curative” non-hormonal therapeutics for cancers, including colon and endometrial cancer.

Women’s Health

Introducing the first potential “curative” non-hormonal therapeutic for under-addressed women’s health indications, including endometriosis, adenomyosis, and fibroids.

Pioneering the first targeted, nonsurgical, definitive imaging probes for diseases like endometriosis and colon cancer.

Diagnostics

Our Mission:

Our Innovative Technology

Technology
Grid.png

Targeted Dual-Mode Solution:

Our therapeutic and diagnostic peptides employ a two-mode mechanism ensuring activity is confined to diseased cells, not healthy tissue. This specificity allows for targeted therapeutic intervention and precise imaging, enhancing treatment outcomes and diagnostic precision, all without observed side effects.

Our cell-penetrating peptides uniquely target acidic, diseased cells, enabling precise targeting of diseased tissues with unprecedented accuracy.

Our peptides bind to novel non-hormonal intracellular targets found exclusively in pathogenic cells. This approach addresses the root causes of diseases, maximizing efficacy and minimizing side effects while preserving fertility.

MRI
Portfolio

Key Product Portfolio Highlights

Therapeutics

  • ENDO-205: An investigational non-hormonal, disease-modifying therapeutic for endometriosis and endometrial cancer

  • ENDO-995: An investigational first-in-class disease-modifying therapeutic for colon cancer

Diagnostics

  • ENDO-210: An investigational MRI imaging agent with the potential for definitive noninvasive diagnosis of endometriosis

  • ENDO-311: An investigational MRI imaging agent with the potential for definitive noninvasive diagnosis of colon cancer

Modern Building
News

News

ENDOMETRIOSIS RESEARCH TO DEVELOP NON-INVASIVE TREATMENT AND DIAGNOSIS

"The company’s lab, supported by an NICHD small business grant, is cultivating tiny molecules that invade and kill endometrial cells at the source, stopping them from spreading and growing painful lesions."

1200px-The_University_of_California_UCLA.svg.png

ALUMNA CREATES COMPANY TO DEVELOP NONHORMONAL ENDOMETRIOSIS TREATMENT

“I like to say that endometriosis attacked the wrong girl, because we’re fighting back,” Petrossian said. “A disease that attacks 10 percent of our girls and women worldwide attacks all of us, so let’s wipe it out.”

Daily Bruin.PNG

TANYA PETROSSIAN DISCUSSES ENDOMETRIOSIS

Dr. Petrossian is fighting against an overlooked epidemic that affects more than 10 percent of girls and women worldwide.

Contact

Partner with us

Your details were sent successfully!

Address: 5270 California Ave, Suite 300 Irvine, CA 92617

Subscribe

Stay up to date

Subscribe
bottom of page